TESARO, Inc. (TSRO)

74.96
NASDAQ
Prev Close 74.96
Day Low/High 0.00 / 0.00
52 Wk Low/High 23.41 / 75.16
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

NAFTA, GE, Apple and Tesaro

The market is doing well early into the new trading week. The Dow is up some 250 points to new all-time highs as investors applaud the new NAFTA agreement. I think this deal is timely given the ISM manufacturing index in September fell slightly on c...

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

My Biotech Mailbag Is Back

My Biotech Mailbag Is Back

I'll answer some of frequent questions I am hearing from readers in recent weeks.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.

Ophthotech Soars After Third-Quarter Results -- Biotech Movers

Ophthotech Soars After Third-Quarter Results -- Biotech Movers

The New York-based firm reported net income of $5.25 per share, compared with a net loss of $1.71 per share, in the same period a year ago.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

These Stocks Show a Change of Direction

These Stocks Show a Change of Direction

Finding bullish and bearish reversals in the market.

Invest Like a Venture Capitalist With These 4 Stocks

Invest Like a Venture Capitalist With These 4 Stocks

Here's a closer look at four of venture capital funds' favorite publicly traded names in 2017.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Tesaro downgraded at Leerink

Biotech Heating up on M&A Speculation

The market is pretty close to where it was during our last update at noon EST. So far it has been a nicely green day across the board. Oncology mid-cap concern Tesaro  is not giving up its big takeover speculation rise yesterday and is up another 3%...

Tesaro, Clovis Oncology Lifting Biotechs

Market are still slightly down across the board as we approach the noon hour. Biotech is hanging in there well despite shellacking Gilead Sciences  is taking after ratcheting down guidance. Helping the market is mid-cap concern Tesaro , which is cur...

3 Biotechs Screaming 'Takeover Target'

3 Biotechs Screaming 'Takeover Target'

M&A activity should perk up substantially in the small and mid-cap space this year.

Closing Bell: Stocks Lifted by Oil Prices; Facebook Launches Work-Friendly Social Network

Closing Bell: Stocks Lifted by Oil Prices; Facebook Launches Work-Friendly Social Network

U.S. stocks closed higher Monday as oil prices gained steam and Wall Street looked ahead to the start of earnings season.

Trending Tickers: MRK, BMY, TSRO, TWLO, CRM

Trending Tickers: MRK, BMY, TSRO, TWLO, CRM

Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.